Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, announced today the appointment of Erik van den Berg as Chair and independent Board Member of its Supervisory Board. Erik holds a Master’s degree in Chemistry from the University of Utrecht, the Netherlands, and a MBA from Manchester Business School (UK). He has over 25 years’ of experience in the pharmaceutical and biotechnology industries as co-founder, Executive Manager and Supervisory Board member.
Erik started his career in the Biotech industry as Business Developer at IsoTis OrthoBiologics, Inc (SWX/Euronext: ISON – sold to Integra Lifesciences). Subsequently, he worked several years as Senior Executive for Organon, where he was responsible for global biotechnology business development. Since 2007, Erik has been involved at AM-Pharma, as Chief Business Officer (2007-2011) and Chief Executive Officer (2011 – to date). Simultaneously, he co-founded Lava Therapeutics B.V. (NASDAQ: LVTX), at which he fulfilled the roles of (executive) Chairman and Non-Executive Director, and he was independent non-executive Board Members of Lead Pharma (2016-2022) and Step Pharma (2016 – to date). Currently, he serves as chairman of the Supervisory Board at both Step Pharma and Tridek-One. Earlier, he was co-founder and Chairman of the Board of Directors at HeatMatrix Group (sold to BosNieuwkerk) between 2008-2022 and Board Member at HollandBIO, a Dutch Biotechnology Organization, between 2015-2021. Over the years, Erik has been involved in the execution of over 20 transactions and partnerships, including a $600M alliance with Pfizer, $290M partnership with Kyowa Kirin and raised close to €500M in equity and debt financing for biotechnology companies from seed through IPO.
Erik van den Berg, Chair of the Board TargED Biopharmaceuticals says: “I am particularly enthusiastic about contributing, as Chair, to the development of the best-in-class thrombolytic agent (Microlyse) to meet the needs of patients suffering from various forms of Thrombosis. I would also like to thank all of the Board’s members, and the TargED team, for the trust they have put in me. I firmly believe in the Company’s prospects, and look forward to sharing my experience in the global development of new therapeutics.”
Kristof Vercruysse, CEO of TargED Biopharmaceuticals commented: “We are honored to have Erik van den Berg join as independent Chair of the TargED Board. With his extensive experience and outstanding track record in biotechnology business development we are convinced that Erik will be a valuable contributor for TargED as we continue to develop our main compound Microlyse to better the treatment of Thrombosis”.
About TargED Biopharmaceuticals
TargED Biopharmaceuticals B.V. is a biotechnology company and spin-off of the University Medical Center Utrecht, that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted ’ thrombolysis. The lead compound is
Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.